These analyses considered patients with type 1 diabetes mellitus (T1DM) in Canada [8], England/UK [9–12], Spain [13] and the USA [14], T2DM on basal-bolus insulin treatment in Spain [15], patients with diabetes on intensive insulin treatment in the USA [16] and T1DM and T2DM patients receiving multiple daily insulin in Argentina [17]. The gene discussed is INS; the disease is type 2 diabetes mellitus.